Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHL 2011: PET-Driven Treatment in Hodgkin Lymphoma
NCT01358747Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- May 2011
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of BEACOPP, bleomycin + dacarbazine + doxorubicin + vinblastine in Hodgkin lymphoma (HL), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Started May 2011; status: completed.
02
Drugs
BEACOPPbleomycin + dacarbazine + doxorubicin + vinblastine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01358747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01358747.